Glembatumumab vedotin
As of the edition of 20 October 2026, Glembatumumab vedotin is an antibody drug conjugate: stopped in 2018; acts on GPNMB, TUBB and TUBB1 and 7 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2018
- Kind
- Antibody drug conjugate
- Registered trials
- 9, 4 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Eye
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
10 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product10 company-target rows are on route A because of Glembatumumab vedotin.
See the 10 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| TUBB4A | Tubulin beta-4A chain | P04350 |
| TUBB | Tubulin beta chain | P07437 |
| TUBB4B | Tubulin beta-4B chain | P68371 |
| TUBB3 | Tubulin beta-3 chain | Q13509 |
| TUBB2A | Tubulin beta-2A chain | Q13885 |
| GPNMB | Transmembrane glycoprotein NMB | Q14956 |
| TUBB8 | Tubulin beta-8 chain | Q3ZCM7 |
| TUBB6 | Tubulin beta-6 chain | Q9BUF5 |
| TUBB2B | Tubulin beta-2B chain | Q9BVA1 |
| TUBB1 | Tubulin beta-1 chain | Q9H4B7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 7 | 4 | 0 | 3 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Celldex Therapeutics | Lead sponsor of trials |